Program
FHND-9041
A development code. Also written as “FHND9041”.
In Sino Biopharmaceutical's pipeline, EGFR抑制剂 (第三代)
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.
Furthest: phase 3, since Dec 23, 20241 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 3since Dec 23, 2024 | Dec 23, 2024 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
FHND9041
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2024First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06759857 · 350 planned · China
TargetBeta
“EGFR抑制剂 (第三代)”the company's pipeline, read by Claude · source
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06759857Carcinoma, Non-Small-Cell Lung · China | 3 | By invitation | Mar 4, 2025 | 350 |
How it is read
Names in the registry
- “FHND9041”, 1 entry
Codes read as this program: FHND9041.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.